Press "Enter" to skip to content

Category: Sexual health

ARQ 197 demonstrates 66 percent improvement in median PFS in individuals with advanced NSCLC ArQule.

ARQ 197 is also currently being evaluated in scientific trials as a single agent and in combination with other anti-cancer therapies in several indications, including c-Met-associated soft-tissue sarcomas, hepatocellular carcinoma, pancreatic adenocarcinoma, germ cell tumors and colorectal cancer. Sufferers, physicians and other healthcare professionals seeking more information regarding trials concerning ARQ 197 may call 1-800-373-7827. The American Tumor Society’s estimates of the effect of lung cancer in the U.S. During 2009 include 219 approximately,000 new instances and 159,000 deaths resulting from the condition, accounting for 28 % of most cancer deaths. Lung cancer is the leading cause of cancer death among men and women.. Continue reading ARQ 197 demonstrates 66 percent improvement in median PFS in individuals with advanced NSCLC ArQule.